Your only mesothelioma treatment options news source!
Click on each item to read full story.

 
Mesothelioma Compensation Center Shares University of Montana's History of Asbestos With Diagnosed Victims and Urges ...
read story
WASHINGTON, March 3, 2015 /PRNewswire/ -- The Mesothelioma Compensation Center says, "The best weapon any diagnosed victim of a rare cancer can have is knowledge, which is why we wanted to share the University of Montana's history of asbestos exposure. The Mesothelioma Compensation Center says, "We want every diagnosed victim of mesothelioma in the United States to read the University of Montana ...
 
Mesothelioma Compensation Center Urges US Navy Veterans With Mesothelioma to Call for a Customized List of Tips on How ...
read story
WASHINGTON, Feb. 26, 2015 /PRNewswire/ -- The Mesothelioma Compensation Center is now offering US Navy Veterans who have been diagnosed with mesothelioma and/or their family member a list of helpful tips related to compensation, if Medicare allows them to seek treatment from a major...
 
Mesothelioma Victims Center Offers Valuable Information and Guidance for Power Plant Workers Diagnosed with ...
read story
WASHINGTON, Feb. 27, 2015 /PRNewswire/ -- The Mesothelioma Victims Center is now making the best possible compensation a reality for former power plant workers who have been diagnosed with mesothelioma, because these types of individuals could qualify for multi-million dollar mesothelioma settlements. The Mesothelioma Victims Center is making the best possible compensation for former power plant ...
 
Conference on Mesothelioma Co-Hosted with National Cancer Institute
read story
On March 2-4, the Mesothelioma Applied Research Foundation and the National Cancer Institute (NCI) will co-host the annual International Symposium on Malignant Mesothelioma at the National Institutes of Health (NIH). (PRWeb February 27, 2015) Read the full story at http://www.prweb.com/releases/2015/03/prweb12551221.htm
 
Mesothelioma Compensation Center Launches New Campaign for Diagnosed Power Plant Workers by Connecting Them to the ...
read story
WASHINGTON, Feb. 3, 2015 /PRNewswire/ -- The Mesothelioma Compensation Center says, "We are launching a new campaign focused on power plant workers in any state who want instant access to the nation's most skilled mesothelioma compensation lawyers. We would like nothing more than to have a one-on-one conversation with a former worker or family member of a worker and explain how these types of ...
 
Research Study Highlights Promising New Mesothelioma Therapies, According to Surviving Mesothelioma
read story
One of the country’s top mesothelioma researchers has published a new summary of some of the most promising emerging therapies for the deadly cancer. (PRWeb February 25, 2015) Read the full story at http://www.prweb.com/releases/2015/02/prweb12536377.htm
 
New Drug Receives FDA Approval as Orphan Drug for the Treatment of Mesothelioma
read story
Mesothelioma lawyers of The Law Office of Melinda J. Helbock A.P.C. say the FDA’s approval of a drug designed to kill cancer stem cells as “orphan drug designation” gives hope to the future of mesothelioma patients. (PRWeb February 27, 2015) Read the full story at http://www.prweb.com/releases/mesothelioma-drug/fda-designation/prweb12549108.htm
 
Verastem Receives Orphan Drug Designation from FDA for VS-5584 in Mesothelioma
read story
Verastem, Inc. , focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that VS-5584 has received orphan drug designation from the U.S.
 
Novocure Enrolls the First Patient in its Phase II STELLAR Trial of Tumor Treating Fields Together with Pemetrexed and ...
read story
Novocure, a commercial stage oncology company, announced today that the first patient has been enrolled in the STELLAR trial, an open-label, single-arm Phase II trial of Tumor Treating Fields together with pemetrexed and cisplatin or carboplatin in patients with newly diagnosed, unresectable malignant mesothelioma.
 
FDA grants orphan drug status for Verastem' VS-5584 to treat mesothelioma
read story
The US Food and Drug Administration (FDA) has granted orphan drug designation for Verastem's orally available compound VS-5584 for use in the treatment of mesothelioma.